BMS-200475. Anti-HBV

Drugs of the Future

Volumn 24, Issue 11, 1999, Pages 1173-1177

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR DIPIVOXIL; CLEVUDINE; DNA POLYMERASE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS B VIRUS; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; VERTIGO; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0343851667     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.11.549510     Document Type: Review

References (25)

1. Zahler, R., Slusarchyk, W.A. (Bristol-Myers Squibb Co.). Hydroxymethyl(methylenecyclopentyl)purines and pyrimidines. EP 481754, JP 92282373, US 5206244.
2. Bisacchi, G.S., Sundeen, J.E. (Bristol-Myers Squibb Co.). Improved process for preparing the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1, 9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one. WO 9809964.
3. Bisacchi, G.S., Chao, S.T., Bachard, C. et al. BMS-200475, a novel carboxylic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Bioorg Med Chem Lett 1997, 7: 127-32.
4. World Health Organization. Executive summary. In: World Health Report 1996. World Health Organization, Geneva, Switzerland, 1996.
5. Van Damme, P., Tormans, G., Beutels, P., Van Doorslaer, E. Hepatitis B prevention in Europe: A preliminary economic evaluation. Vaccine 1995, 13: S54-7.
6. Zuckerman, A.J., Sun, T.-T., Linsell, A., Stjernsward, J. Prevention of primary liver cancer. Lancet 1983, 1: 463-5.
7. Zuckerman, J.N. New recombinant hepatitis B DNA vaccines. Drug News Perspect 1999, 12: 473-6.
8. Slusarchyk, W.A., Field, A.K., Greytok, J.A., Taunk, P., Toumari, A.V., Young, M.G., Zahler, R. 4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl purines and pyrimidines, a new class of anti-herpesvirus agents. Antivir Res 1992, 17(Suppl. 1): Abst 102.
9. Colonno, R.J., Innaimo, S.F., Seifer, M. et al. Identification of BMS-200475 as a novel and potent inhibitor of hepatitis B virus replication. Antivir Res 1997, 34(2): Abst 32.
10. Innaimo, S.F., Seifer, M., Genovesi, E. et al. Identification of BMS-200475, as a novel and potent inhibitor of hepatitis B virus. 36th Intersci Conf Antimcirob Agents Chemother (Sept 16-18, New Orleans) 1996, Abst H24.
11. Innaimo, S.F., Seifer, M., Bisacchi, G.S., Standring, D.N., Zahler, R., Colonno, R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997, 41: 1444-8.
12. Yamanaka, G., Wilson, T.M., Innaimo, S.F., Colonno, R.J. BMS-200475, a new anti-hepatitis B compound: Metabolic studies and comparison with 3TC, penciclovir, and lobucavir. Antivir Res 1997, 34(2): Abst 78.
13. Seifer, M., Hamatake, R.K., Colonno, R.J., Standring, D.N. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998, 42: 3200-8.
14. Genovesi, E.V., Lamb, L., Medina, I., Taylor, D., Seifer, M., Innaimo, S., Colonno, R.J., Standring, D.N., Clark, J.M. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998, 42: 3209-17.
15. Genovesi, E.V., Lamb, L.M., Medina, I. et al. Carbocyclic guanosine nucleoside BMS-200475 treatment inhibits woodchuck hepatitis virus (WHV) viremia in WHV-carriers. Antivir Res 1997, 34(2): Abst 82.
16. Clark, J.M., Genovesi, E.V., Medina, I., Lamb, L., Taylor, D., Standring, D., Seifer, M., Innaimo, S., Colonno, R.J. Maintenance therapy with BMS-200475, in the woodchuck model of chronic hepatitis B infection. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst H-10.
17. Colonno, R., Medina, I., Lamb, C., Genovesi, E., Clark, J. Maintenance of viral suppression in chronically-infected woodchucks with weekly dosing of BMS-200475. Hepatology 1998, 28(4, Part 2, Suppl.): Abst 1304.
18. Marion, P.L., Colonno, R.J. Evaluation of BMS-200475 and lobucavir in the duck model of hepatitis B virus infection. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24-27, San Diego) 1998, Abst H-49.
19. Yamanaka, G., Wilson, T., Innaimo, S., Bisacchi, G.S., Egli, P., Rinehart, J.K., Zahler, R., Colonno, R.J. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999, 43: 190-3.
20. Yamanaka, G., Innaimo, S.F., Wilson, T.M., Standring, D.N., Zahler, R., Colonno, R.J. Metabolic studies on BMS-200475, a new antiviral compound with activity against hepatitis B virus. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F171.
21. Grasela, D.M., Kelly, E.A., Olsen, S.J., D'Arienzo, C., Hiles, C., Gale, P.J., Birkhofer, M.J. BMS-200475: Single oral dose safety and pharmacokinetic study in healthy volunteers. 37th Intersci Conf Antimicrob Agents Chemother (Sept 27-Oct 1, Toronto) 1997, Abst H-33.
22. BMS-200475 development status. Bristol-Myers Squibb Company Communication Aug 4, 1999.
23. Bisacchi, G.S., Sundeen, J.E., Slusarchyk, W.A. et al. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Antivir Res 1997, 34(2): Abst 77.
24. Bisacchi, S. Anti-HBV nucleoside analogs. 216th ACS Natl Meet (Aug 23-27, Boston) 1998, Abst MEDI 373.
25. Genovesi, E.V., Lamb, L., Medina, I. et al. Efficacy of the novel nucleoside BMS-200475 in the woodchuck model of chronic hepatitis B infection. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst F173.